A Clinical Study Evaluating the Safety, Tolerability, and Efficacy of MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism

NCT06747247 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

98

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis

Interventions

DRUG: Long-term Dosing Cohort
DRUG: Single ascending doses of MT1013
DRUG: Multiple ascending doses of MT1013

Sponsor

Shaanxi Micot Pharmaceutical Technology Co., Ltd.